LNTH · Lantheus Holdings, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net income, as a percentage of revenues non-GAAP | 26.2% | Six Months Ended June 30, 2026 | — |
| Adjusted operating income (non-GAAP) non-GAAP | $142M | Q2 2026 | — |
|
|
|||
| Adjusted operating income, as a percentage of revenues non-GAAP | 35.4% | Six Months Ended June 30, 2026 | — |
| Free cash flow | 211.77M | Six Months Ended June 30 | — |
|
|
|||
| Sales of DEFINITY | $88.3M | Q2 2026 | +5.2% |
|
|
|||
| Sales of Neuraceq | $39.6M | Q2 2026 | — |
|
|
|||
| Sales of PYLARIFY | $240.4M | Q2 2026 | -4.1% |
|
|
|||
| DEFINITY | 330.25M | Twelve Months Ended December 31, 2025 | — |
| Net cash provided by operating activities | $90.2M | Three Months Ended December 31, 2025 | — |
| Neuraceq | 51.45M | Twelve Months Ended December 31, 2025 | — |
| Other precision diagnostics | 24.62M | Twelve Months Ended December 31, 2025 | — |
| PYLARIFY | 989.12M | Twelve Months Ended December 31, 2025 | — |
| Strategic partnerships and other revenue | 59.38M | Twelve Months Ended December 31, 2025 | — |
| TechneLite | 86.8M | Twelve Months Ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LNTH
this stock
Lantheus Holdings, Inc.
|
$6.59B | +51.7% | +3.6% | 24.2 | 9.7% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.49B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LNTH | +0.0% | -6.2% | +37.5% | +1.3% | +51.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -0.4% | -10.6% | +23.7% | -2.6% | +37.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.